Annual EBITDA
-$7.53 M
+$252.90 K+3.25%
30 June 2024
Summary:
InMed Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$7.53 million, with the most recent change of +$252.90 thousand (+3.25%) on 30 June 2024. During the last 3 years, it has risen by +$2.08 million (+21.68%). INM annual EBITDA is now -16023.98% below its all-time high of -$46.70 thousand, reached on 30 June 2013.INM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$1.61 M
+$247.80 K+13.34%
30 September 2024
Summary:
InMed Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$1.61 million, with the most recent change of +$247.80 thousand (+13.34%) on 30 September 2024. Over the past year, it has increased by +$865.70 thousand (+34.98%). INM quarterly EBITDA is now -118.62% below its all-time high of $8.64 million, reached on 30 June 2007.INM Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$6.66 M
+$865.70 K+11.50%
30 September 2024
Summary:
InMed Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently -$6.66 million, with the most recent change of +$865.70 thousand (+11.50%) on 30 September 2024. Over the past year, it has increased by +$263.00 thousand (+3.80%). INM TTM EBITDA is now -185.41% below its all-time high of $7.80 million, reached on 31 March 2008.INM TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INM EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +3.3% | +35.0% | +3.8% |
| 3 y3 years | +21.7% | +43.3% | +38.8% |
| 5 y5 years | +24.7% | +43.5% | +37.5% |
INM EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +43.3% | -340.5% | +61.3% | -10.4% | +51.6% |
| 5 y | 5 years | at high | +43.3% | -340.5% | +61.3% | -10.4% | +51.6% |
| alltime | all time | <-9999.0% | +43.3% | -118.6% | +61.3% | -185.4% | +51.6% |
InMed Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$1.61 M(-13.3%) | -$6.66 M(-11.5%) |
| June 2024 | -$7.53 M(-3.2%) | -$1.86 M(+12.9%) | -$7.53 M(+24.7%) |
| Mar 2024 | - | -$1.65 M(+6.0%) | -$6.04 M(-5.5%) |
| Dec 2023 | - | -$1.55 M(-37.3%) | -$6.39 M(-7.7%) |
| Sept 2023 | - | -$2.48 M(+577.5%) | -$6.93 M(-11.0%) |
| June 2023 | -$7.78 M(-41.4%) | -$365.30 K(-81.7%) | -$7.78 M(-24.5%) |
| Mar 2023 | - | -$2.00 M(-4.2%) | -$10.31 M(-11.9%) |
| Dec 2022 | - | -$2.09 M(-37.3%) | -$11.70 M(-15.1%) |
| Sept 2022 | - | -$3.33 M(+15.1%) | -$13.77 M(+3.7%) |
| June 2022 | -$13.28 M(+38.1%) | -$2.89 M(-14.6%) | -$13.28 M(-2.3%) |
| Mar 2022 | - | -$3.39 M(-18.6%) | -$13.60 M(+2.6%) |
| Dec 2021 | - | -$4.16 M(+46.6%) | -$13.26 M(+21.8%) |
| Sept 2021 | - | -$2.84 M(-11.6%) | -$10.88 M(+13.6%) |
| June 2021 | -$9.61 M(+8.9%) | -$3.21 M(+5.4%) | -$9.58 M(+20.4%) |
| Mar 2021 | - | -$3.05 M(+70.6%) | -$7.96 M(+15.2%) |
| Dec 2020 | - | -$1.79 M(+16.3%) | -$6.91 M(-9.0%) |
| Sept 2020 | - | -$1.54 M(-3.4%) | -$7.59 M(-14.8%) |
| June 2020 | -$8.83 M(-11.8%) | -$1.59 M(-20.4%) | -$8.90 M(-14.3%) |
| Mar 2020 | - | -$2.00 M(-19.0%) | -$10.39 M(-5.6%) |
| Dec 2019 | - | -$2.47 M(-13.5%) | -$11.01 M(+3.2%) |
| Sept 2019 | - | -$2.85 M(-7.3%) | -$10.66 M(+6.3%) |
| June 2019 | -$10.00 M(+54.9%) | -$3.07 M(+17.5%) | -$10.03 M(+9.0%) |
| Mar 2019 | - | -$2.62 M(+23.2%) | -$9.21 M(+11.8%) |
| Dec 2018 | - | -$2.12 M(-4.2%) | -$8.24 M(+12.5%) |
| Sept 2018 | - | -$2.22 M(-1.4%) | -$7.32 M(+11.8%) |
| June 2018 | -$6.46 M(+91.9%) | -$2.25 M(+36.5%) | -$6.55 M(+13.5%) |
| Mar 2018 | - | -$1.65 M(+36.7%) | -$5.77 M(+14.7%) |
| Dec 2017 | - | -$1.21 M(-16.4%) | -$5.03 M(+11.6%) |
| Sept 2017 | - | -$1.44 M(-1.9%) | -$4.50 M(+33.9%) |
| June 2017 | -$3.36 M(+90.1%) | -$1.47 M(+62.1%) | -$3.36 M(+48.1%) |
| Mar 2017 | - | -$907.30 K(+32.9%) | -$2.27 M(+38.6%) |
| Dec 2016 | - | -$682.70 K(+125.5%) | -$1.64 M(+9.3%) |
| Sept 2016 | - | -$302.70 K(-20.1%) | -$1.50 M(-11.7%) |
| June 2016 | -$1.77 M(-47.6%) | -$378.80 K(+38.0%) | -$1.70 M(-32.5%) |
| Mar 2016 | - | -$274.50 K(-49.4%) | -$2.51 M(-28.2%) |
| Dec 2015 | - | -$542.70 K(+8.4%) | -$3.50 M(+2.1%) |
| Sept 2015 | - | -$500.50 K(-58.2%) | -$3.43 M(-1.6%) |
| June 2015 | -$3.38 M(+193.6%) | -$1.20 M(-5.2%) | -$3.49 M(+5.5%) |
| Mar 2015 | - | -$1.26 M(+167.8%) | -$3.31 M(+54.8%) |
| Dec 2014 | - | -$471.30 K(-15.4%) | -$2.14 M(+25.7%) |
| Sept 2014 | - | -$557.40 K(-45.1%) | -$1.70 M(+47.4%) |
| June 2014 | -$1.15 M(+2365.3%) | -$1.01 M(+999.5%) | -$1.15 M(+615.0%) |
| Mar 2014 | - | -$92.30 K(+162.2%) | -$161.30 K(+110.6%) |
| Dec 2013 | - | -$35.20 K(+220.0%) | -$76.60 K(+116.4%) |
| Sept 2013 | - | -$11.00 K(-51.8%) | -$35.40 K(-25.2%) |
| June 2013 | -$46.70 K | -$22.80 K(+200.0%) | -$47.30 K(-53.2%) |
| Mar 2013 | - | -$7600.00(-226.7%) | -$101.10 K(-13.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2012 | - | $6000.00(-126.2%) | -$116.20 K(-21.8%) |
| Sept 2012 | - | -$22.90 K(-70.1%) | -$148.50 K(-10.8%) |
| June 2012 | -$168.60 K(-5.4%) | -$76.60 K(+237.4%) | -$166.40 K(+490.1%) |
| Mar 2012 | - | -$22.70 K(-13.7%) | -$28.20 K(-86.0%) |
| Dec 2011 | - | -$26.30 K(-35.5%) | -$201.30 K(+7.3%) |
| Sept 2011 | - | -$40.80 K(-166.2%) | -$187.60 K(+7.7%) |
| June 2011 | -$178.20 K(-47.9%) | $61.60 K(-131.5%) | -$174.20 K(-46.5%) |
| Mar 2011 | - | -$195.80 K(+1454.0%) | -$325.70 K(+51.5%) |
| Dec 2010 | - | -$12.60 K(-54.0%) | -$215.00 K(-25.2%) |
| Sept 2010 | - | -$27.40 K(-69.5%) | -$287.40 K(-14.4%) |
| June 2010 | -$341.90 K(-43.8%) | -$89.90 K(+5.6%) | -$335.70 K(+2.2%) |
| Mar 2010 | - | -$85.10 K(+0.1%) | -$328.40 K(-1.4%) |
| Dec 2009 | - | -$85.00 K(+12.3%) | -$333.10 K(-32.9%) |
| Sept 2009 | - | -$75.70 K(-8.4%) | -$496.70 K(-23.4%) |
| June 2009 | -$608.20 K(-48.8%) | -$82.60 K(-8.0%) | -$648.40 K(-42.7%) |
| Mar 2009 | - | -$89.80 K(-63.9%) | -$1.13 M(-2.4%) |
| Dec 2008 | - | -$248.60 K(+9.3%) | -$1.16 M(-6.9%) |
| Sept 2008 | - | -$227.40 K(-59.8%) | -$1.24 M(-11.4%) |
| June 2008 | -$1.19 M(+21.9%) | -$565.70 K(+381.4%) | -$1.41 M(-118.0%) |
| Mar 2008 | - | -$117.50 K(-64.8%) | $7.80 M(+1.4%) |
| Dec 2007 | - | -$334.20 K(-13.9%) | $7.70 M(+2.8%) |
| Sept 2007 | - | -$388.10 K(-104.5%) | $7.49 M(-2.8%) |
| June 2007 | -$973.40 K(+5.7%) | $8.64 M(-3980.9%) | $7.70 M(-761.5%) |
| Mar 2007 | - | -$222.70 K(-58.8%) | -$1.16 M(-12.2%) |
| Dec 2006 | - | -$540.70 K(+208.8%) | -$1.33 M(+33.0%) |
| Sept 2006 | - | -$175.10 K(-22.6%) | -$997.20 K(-9.7%) |
| June 2006 | -$920.80 K(-40.1%) | -$226.10 K(-41.2%) | -$1.10 M(-20.4%) |
| Mar 2006 | - | -$384.40 K(+81.7%) | -$1.39 M(+20.0%) |
| Dec 2005 | - | -$211.60 K(-24.9%) | -$1.16 M(-1.5%) |
| Sept 2005 | - | -$281.90 K(-44.7%) | -$1.17 M(-22.9%) |
| June 2005 | -$1.54 M(+62.3%) | -$509.80 K(+233.4%) | -$1.52 M(+8.3%) |
| Mar 2005 | - | -$152.90 K(-33.3%) | -$1.41 M(-2.3%) |
| Dec 2004 | - | -$229.40 K(-63.7%) | -$1.44 M(-0.3%) |
| Sept 2004 | - | -$631.30 K(+60.5%) | -$1.44 M(+50.4%) |
| July 2004 | -$946.80 K(+5.2%) | -$393.40 K(+111.5%) | -$960.40 K(+2.8%) |
| Apr 2004 | - | -$186.00 K(-20.3%) | -$934.10 K(+4.2%) |
| Jan 2004 | - | -$233.30 K(+58.0%) | -$896.10 K(+7.4%) |
| Oct 2003 | - | -$147.70 K(-59.8%) | -$834.20 K(-2.5%) |
| July 2003 | -$900.10 K(-0.7%) | -$367.10 K(+148.0%) | -$855.50 K(+37.4%) |
| Apr 2003 | - | -$148.00 K(-13.7%) | -$622.60 K(-9.3%) |
| Jan 2003 | - | -$171.40 K(+1.4%) | -$686.50 K(-11.7%) |
| Oct 2002 | - | -$169.00 K(+25.9%) | -$777.60 K(-12.5%) |
| July 2002 | -$906.10 K(-55.5%) | -$134.20 K(-36.7%) | -$889.00 K(+17.8%) |
| Apr 2002 | - | -$211.90 K(-19.3%) | -$754.80 K(+39.0%) |
| Jan 2002 | - | -$262.50 K(-6.4%) | -$542.90 K(+93.6%) |
| Oct 2001 | - | -$280.40 K | -$280.40 K |
| July 2001 | -$2.04 M | - | - |
FAQ
- What is InMed Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for InMed Pharmaceuticals?
- What is InMed Pharmaceuticals annual EBITDA year-on-year change?
- What is InMed Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for InMed Pharmaceuticals?
- What is InMed Pharmaceuticals quarterly EBITDA year-on-year change?
- What is InMed Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for InMed Pharmaceuticals?
- What is InMed Pharmaceuticals TTM EBITDA year-on-year change?
What is InMed Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of INM is -$7.53 M
What is the all time high annual EBITDA for InMed Pharmaceuticals?
InMed Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is -$46.70 K
What is InMed Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, INM annual earnings before interest, taxes, depreciation & amortization has changed by +$252.90 K (+3.25%)
What is InMed Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of INM is -$1.61 M
What is the all time high quarterly EBITDA for InMed Pharmaceuticals?
InMed Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $8.64 M
What is InMed Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, INM quarterly earnings before interest, taxes, depreciation & amortization has changed by +$865.70 K (+34.98%)
What is InMed Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of INM is -$6.66 M
What is the all time high TTM EBITDA for InMed Pharmaceuticals?
InMed Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $7.80 M
What is InMed Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, INM TTM earnings before interest, taxes, depreciation & amortization has changed by +$263.00 K (+3.80%)